Back to results
US 2023/0398146 A1Published application
Immune modulation of myeloid derived suppressive cell function for cancer treatment
AssigneeSURGE Therapeutics, Inc.
InventorMichael Solomon Goldberg
Life of this patent
Estimating the term…
Abstract
The present disclosure provides technologies related to compositions each comprising a biomaterial preparation and a modulator of myeloid-derived suppressive cell function (e.g., a modulator of neutrophil function) as well as uses thereof for cancer treatment.
Claims29
A method comprising a step of:
- intraoperative administration at a tumor resection site of a subject suffering from cancer:
- a combination of a biomaterial preparation and a modulator of myeloid-derived suppressive cell function.
5-7. (canceled)
(canceled)
12-16. (canceled)
The method of claim 13, wherein the carbohydrate polymer is or comprises (i) hyaluronic acid or (ii) chitosan or a modified chitosan.
18-20. (canceled)
25-26. (canceled)
28-32. (canceled)
35-36. (canceled)
39-43. (canceled)
46-48. (canceled)
A method comprising steps of:
- resecting a tumor in a subject suffering from cancer;
- and
- administering at the tumor resection site an extended-release, monotherapeutic polymeric biomaterial formulation of a modulator of myeloid-derived suppressive cell function,
- wherein the step of administration excludes (i) adoptive transfer of T cells to the subject;
- (ii) administration of a tumor antigen to the subject;
- and (iii) administration of a microparticle to the subject.
3 more elements
Dependencies are inferred from the claim text.